NASDAQ: GELSGelteq Ltd Stock
$2.07-0.26 (-11.16%)
Updated Apr 29, 2025
GELS Price
$2.07
Fair Value Price
N/A
Market Cap
$19.54M
52 Week Low
$0.77
52 Week High
$5.50
P/E
-7.24x
P/B
1.99x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$2.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$714k
Beta
2.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GELS Overview
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GELS's potential to beat the market
- GELS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
GELS
RankedUnranked of 58
RankedUnranked of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.75 | A | |
| $32.49 | A | |
| $27.00 | A |
Be the first to know about important GELS news, forecast changes, insider trades & much more!
GELS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GELS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GELS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GELS is good value based on its book value relative to its share price (1.99x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.09x)
P/B vs Industry Valuation
GELS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GELS due diligence checks available for Premium users.
Valuation
GELS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.24x
Industry
21.8x
Market
29.19x
GELS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.99x
Industry
2.09x
GELS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GELS's financial health
Profit margin
Revenue
$0.0
Net Income
-$755.4k
Profit Margin
0%
GELS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.8M
Liabilities
$3.8M
Debt to equity
0.37
GELS's short-term liabilities ($2.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GELS's long-term liabilities ($1.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GELS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$201.4k
Investing
-$43.4k
Financing
$165.7k
GELS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GELS vs Pharmaceutical Stocks
Gelteq Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.